FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D

An implanted device for delivering the GLP-1 receptor agonist exenatide to people with type 2 diabetes received a unanimous no vote from an FDA advisory panel based on safety and other concerns.

Related Keywords

Maryland ,United States ,Bethesda ,Erica Brittain ,University Of Colorado Hospital ,Metabolic Drugs Advisory Committee ,Glucose Management Team ,Drug Administration ,Intarcia Therapeutics ,Biostatistics Research Branch ,National Institute ,Infectious Diseases ,Metabolic Drugs Advisory ,Flow Wang ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Acute Kidney Injury Aki ,Acute Kidney Injury ,Eski ,Renal Failure ,Enal Insufficiency ,Idney Insufficiency ,Kidney Failure ,Receptors ,Toxicology ,Adherence ,Dherence To Medication Issues For Patients ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cance ,